The effectivity of lifestyle interventions and prevention in patients with atrial fibrillation referred for ablation; a randomised-controlled trial - Prevention to improve Outcomes after PVI (POP-trial)

Catharina-ziekenhuis0 个研究点目标入组 150 人开始时间: 待定最近更新: 2024年4月15日

适应症

试验速览

暂无简介。

•Patients with paroxysmal or persistent atrial fibrillation referred for initial
•catheter ablation
•Age 18-75 years
•The patient should have at least on treatable risk factor (BMI >=27 kg/m2,
•hyperlipidaemia, hypertension, diabetes mellitus with HbA1c >=53 mmol/mol,
•active smoking, or excess alcohol use)
•Patients are willing and able to use the VitalHealth Engage platform on their
•own preferred device

•Longstanding persistent atrial fibrillation (persistent atrial fibrillation for
•more than 1 year)
•Permanent atrial fibrillation
•Asymptomatic atrial fibrillation
•Prior ablation
•Severe valvular heart disease
•Prior or soon foreseen implantation of cardiac device
•Acute coronary syndroom < 3 months before inclusion
•Unstable heart failure NYHA IV or heart failure necessitating admission <3
•months before inclusion
•Cardia surgery <3 months before inclusion
•Life expectancy <1 year

发起方